A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer

This phase I study is testing a drug called JSB462 (luxdegalutamide) — a new type of androgen receptor degrader — in Japanese men with metastatic prostate cancer who have progressed on standard hormone therapy. The study is checking safety and finding the right dose. **You may be eligible if...** - You are a man with confirmed prostate cancer that has spread to bones or other organs (not just lymph nodes) - Your prostate cancer has failed or is not eligible for standard hormone treatments - Your testosterone levels are at castrate levels (very low, as achieved by hormone therapy or surgical removal of testes) - You are in good physical condition (ECOG 0–1) **You may NOT be eligible if...** - Your prostate cancer has spread to the brain - You have another active cancer - You have had a prior cancer that might recur or interfere Talk to your doctor to see if this trial is right for you.